Literature DB >> 9192462

A random walk rule for phase I clinical trials.

S D Durham1, N Flournoy, W F Rosenberger.   

Abstract

We describe a family of random walk rules for the sequential allocation of dose levels to patients in a dose-response study, or phase I clinical trial. Patients are sequentially assigned the next higher, same, or next lower dose level according to some probability distribution, which may be determined by ethical considerations as well as the patient's response. It is shown that one can choose these probabilities in order to center dose level assignments unimodally around any target quantile of interest. Estimation of the quantile is discussed; the maximum likelihood estimator and its variance are derived under a two-parameter logistic distribution, and the maximum likelihood estimator is compared with other nonparametric estimators. Random walk rules have clear advantages: they are simple to implement, and finite and asymptotic distribution theory is completely worked out. For a specific random walk rule, we compute finite and asymptotic properties and give examples of its use in planning studies. Having the finite distribution theory available and tractable obviates the need for elaborate simulation studies to analyze the properties of the design. The small sample properties of our rule, as determined by exact theory, compare favorably to those of the continual reassessment method, determined by simulation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9192462

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  19 in total

1.  Continual reassessment method with multiple toxicity constraints.

Authors:  Shing M Lee; Bin Cheng; Ying Kuen Cheung
Journal:  Biostatistics       Date:  2010-09-28       Impact factor: 5.899

2.  Quality assessment of phase I dose-finding cancer trials: proposal of a checklist.

Authors:  Sarah Zohar; Qing Lian; Vincent Levy; Ken Cheung; Anastasia Ivanova; Sylvie Chevret
Journal:  Clin Trials       Date:  2008       Impact factor: 2.486

3.  Bayesian hybrid dose-finding design in phase I oncology clinical trials.

Authors:  Ying Yuan; Guosheng Yin
Journal:  Stat Med       Date:  2011-03-01       Impact factor: 2.373

4.  Stochastic Approximation and Modern Model-based Designs for Dose-Finding Clinical Trials.

Authors:  Ying Kuen Cheung
Journal:  Stat Sci       Date:  2010-05       Impact factor: 2.901

5.  Simple benchmark for complex dose finding studies.

Authors:  Ying Kuen Cheung
Journal:  Biometrics       Date:  2014-02-25       Impact factor: 2.571

6.  A Bayesian adaptive design for cancer phase I trials using a flexible range of doses.

Authors:  Mourad Tighiouart; Galen Cook-Wiens; André Rogatko
Journal:  J Biopharm Stat       Date:  2017-10-06       Impact factor: 1.051

7.  Sample size formulae for the Bayesian continual reassessment method.

Authors:  Ying Kuen Cheung
Journal:  Clin Trials       Date:  2013-08-21       Impact factor: 2.486

8.  Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents.

Authors:  Anthe S Zandvliet; Mats O Karlsson; Jan H M Schellens; William Copalu; Jos H Beijnen; Alwin D R Huitema
Journal:  Invest New Drugs       Date:  2009-02-06       Impact factor: 3.850

9.  A comparative study of Bayesian optimal interval (BOIN) design with interval 3+3 (i3+3) design for phase I oncology dose-finding trials.

Authors:  Yanhong Zhou; Ruobing Li; Fangrong Yan; J Jack Lee; Ying Yuan
Journal:  Stat Biopharm Res       Date:  2020-09-14       Impact factor: 1.452

10.  The estimation of minimum effective volume of 0.5% ropivacaine in ultrasound-guided interscalene brachial plexus nerve block: A clinical trial.

Authors:  Kailash Mittal; Sarita Janweja; Pushpender Sangwan; Deepa Agarwal; Himani Tak
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2019 Jan-Mar
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.